Salk scientists add new bond to protein engineering toolbox

Salk scientists add new bond to protein engineering toolbox

By adding covalent bonds to proteins, researchers can design new drugs, imaging agents, or molecules that aid basic research.

 

Suggested Articles

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.

The phase 2/3 clinical trial linked REGN-COV2 to a 57% decline in medical visits associated with COVID-19 in the 29 days after treatment.

Drug companies often face steep challenges when entering new markets for the first time. LianBio is here to help.